https://www.selleckchem.com/pr....oducts/thymidine.htm
This article explores the current status of generally understudied patient groups in NSCLC and proposes future directions in therapeutic strategies. mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in. mutated patients is not clear. Eligible patients diagnosed with NSCLC and foun
Like
Comment
Share
